Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Christopher King, MD PHD
Case Western Reserve University
Principal Investigator - Gary Weil, MD
Washington University School of Medicine
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ministere de la Sante Publique Et de la Population
Port-au-Prince, Haiti
- Vector Control Research Centre
Puducherry, India
- Universitas Indonesia
Jakarta, Indonesia
- Papua New Guinea Institute for Medical Research
Madang, Papua New Guinea
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2016
- Primary completion
- 27 Apr 2017
- Completion
- 31 May 2018
- Last update posted
- 31 Dec 2020
- Registered enrollment
- 23,789
- Registry id
- NCT02899936
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.